With more than half of the U.S. population fully vaccinated and mask mandates being lifted throughout the country, America looks to resume “normal life” before the pandemic took over.
As pharma companies bolster their pipelines via multibillion-dollar acquisitions, drug manufacturers continue to heavily invest in the oncology space.
A recent report written by SVB Leerink analysts that looked at eight companies and their research-and-development portfolios found that in the past five years, they progressed only 24 percent of their new molecular entities to approval.
Just like 2016 and the year before, specialty drugs dominate the 2017 list of top performers in the most recent first year after launch class.
A listing of the the new molecular entities launched in the United States during 2015 that generated 2016 sales of at least $200 million
R&D success and M&A activity loom as large swing factors for the bio sector in 2017 with the regulatory arena potentially at its most amenable for years.
A shift from traditional project management practices, EPC is designed to accelerate drugs to market.
The pharma industry’s R&D concentration has been shifting towards specialty therapy areas as research and development returns decline for some leaders.
Executives from the 2015 and 2014 Manny Award winners and finalists share their views on a variety of industry-related topics.
